ReviewTrends in cardiovascular medicine2026
Pathogenesis of plaque erosion.
Review in Trends in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- From Electrocardiography to the Catheterization Laboratory: A Multimodal Artificial Intelligence Framework for Acute Coronary Syndrome Detection and Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Review
- Microcalcification: Effects on Atherosclerotic Vulnerable Plaques, Detection, and Therapeutic Perspectives.Current atherosclerosis reports · 2026Review
- Limited Utility of Lymphocyte-Based Inflammatory Indices in Troponin-Negative Unstable Angina Pectoris.Journal of cardiovascular development and disease · 2026Article
- Article
- Intracoronary Imaging for the Management of Vulnerable Plaques.Journal of clinical medicine · 2026Review
- Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper.Global heart · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Plaque erosion is the second most common cause of acute coronary syndromes. It occurs in the absence of fibrous cap rupture, and typically shows luminal thrombi in direct contact with an intimal surface that lacks endothelial cells (ECs) but is enriched in smooth muscle cells and proteoglycan matrix. First described almost thirty years ago, plaque erosion accounts for an increasing fraction of acute coronary syndromes, but its frequency decreases with age in both men and women. Although a higher prevalence of erosion in women was suggested based on early observations, this has not been clearly borne out in more recent studies. The pathogenesis of plaque erosion is largely unknown; nevertheless, potential etiologic factors include disturbed flow and altered endothelial shear stress, elements of the innate and adaptive immune systems, hyaluronan and Toll-like receptor 2 signaling, activation of the NRF2 transcription factor, matrix metallopeptidase-mediated disruption of EC-extracellular matrix interactions, and distinct thrombotic mechanisms. While several of these factors are also linked to plaque rupture, existing evidence suggests that the biology of plaque erosion is substantially different from that of rupture; therefore, a deeper understanding of the molecular basis of coronary thrombosis associated with plaque erosion may guide the development of biomarkers and specific preventive or therapeutic strategies for acute coronary syndromes with intact fibrous cap. Such progress would pave the way for personalized care of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.